Perioperative pembrolizumab enhances survival rates in advanced head and neck cancer, paving the way for earlier ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

The U.S. FDA has granted orphan drug designation for Eli Lilly's olomorasib for treatment of KRAS G12C-mutant non-small cell ...

In June 2025, TuHURA initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda ® (pembrolizumab) compared to ...

In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the concurrent treatment of vulvar cancer with chemoradiation and pembrolizumab.Patients who underwent ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

In this video, Susana M. Campos, MD, MPH, discusses results from the final analysis of the phase 3 A18 study in advanced cervical cancer, presented at ASCO Annual Meeting.The ...

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head ...

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the ...